Adma Biologics (ADMA) Revenue (2011 - 2025)

Adma Biologics has reported Revenue for 14 years, with the latest figure at $139.2 million in Q4 2025.

• For the quarter ending Q4 2025, Revenue rose 18.39% year-over-year to $139.2 million; the trailing twelve-month figure through Dec 2025 stood at $510.2 million (up 19.63% YoY), and the FY2025 full-year result was $510.2 million, up 19.63% from the prior year.
• Revenue for Q4 2025 stood at $139.2 million, up from $134.2 million in the prior quarter.
• The five-year high for Revenue was $139.2 million in Q4 2025, with the low at $16.0 million in Q1 2021.
• Historically, Revenue has averaged $77.1 million across 5 years, with a median of $74.5 million in 2022.
• Annual changes were most pronounced in 2022 — Revenue surged 320.63% — and 2023, when it declined 19.84%.
• Adma Biologics' Revenue stood at $55.0 million in 2021, then declined by 9.12% to $50.0 million in 2022, then surged by 47.86% to $73.9 million in 2023, then soared by 59.06% to $117.5 million in 2024, then advanced by 18.39% to $139.2 million in 2025.
• The last three Revenue figures came in at $139.2 million (Q4 2025), $134.2 million (Q3 2025), and $122.0 million (Q2 2025), per Business Quant data.